BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+9.82%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.17B
AUM Growth
+$6.17B
(+0.29%)
Cap. Flow
-$269M
Cap. Flow
% of AUM
-4.35%
Top 10 Holdings %
Top 10 Hldgs %
39.22%
Holding
177
New
11
Increased
57
Reduced
71
Closed
15
Top Buys
| 1 |
Evolent Health
EVH
|
$28.3M |
| 2 |
Exact Sciences
EXAS
|
$19.8M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$19.6M |
| 4 |
Abbott
ABT
|
$15.7M |
| 5 |
Inspire Medical Systems
INSP
|
$14.8M |
Top Sells
| 1 |
Bio-Rad Laboratories Class A
BIO
|
$36.5M |
| 2 |
Insmed
INSM
|
$36.2M |
| 3 |
argenx
ARGX
|
$32M |
| 4 |
Charles River Laboratories
CRL
|
$31.4M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$30.5M |
Sector Composition
| 1 | Healthcare | 99.93% |
| 2 | Industrials | 0.04% |
| 3 | Communication Services | 0.02% |
| 4 | Technology | 0.01% |
| 5 | Consumer Discretionary | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Scholar Rock
SRRK
$3.3B
| $17.3M | 0.28% |
2,161,203
-4,000
| -0.2% | -$32K |
|
77
Fate Therapeutics
FATE
$115M
| $16.9M | 0.27% |
4,839,779
| – | – |
|
78
Esperion Therapeutics
ESPR
$490M
| $16.4M | 0.27% |
9,944,064
| – | – |
|
79
Cencora
COR
$57.2B
| $16.2M | 0.26% |
72,053
-17,276
| -19% | -$3.89M |
|
|
80
Bio-Rad Laboratories Class A
BIO
$7.8B
| $15.4M | 0.25% |
46,151
-109,107
| -70% | -$36.5M |
|
81
Astrana Health
ASTH
$1.42B
| $14.7M | 0.24% |
254,182
+3,565
| +1% | +$207K |
|
|
82
Charles River Laboratories
CRL
$7.99B
| $14.4M | 0.23% |
73,115
-159,587
| -69% | -$31.4M |
|
|
ONC
83
BeOne Medicines Ltd. American Depositary Shares
ONC
$37B
| $13.2M | 0.21% |
58,729
+33,100
| +129% | +$7.43M |
|
84
Generation Bio
GBIO
$40.3M
| $9.68M | 0.16% |
3,918,856
| – | – |
|
85
Phreesia
PHR
$1.81B
| $9.63M | 0.16% |
422,406
-20,935
| -5% | -$477K |
|
86
Humana
HUM
$37.5B
| $9.01M | 0.15% |
28,440
| – | – |
|
87
Terns Pharmaceuticals
TERN
$651M
| $8.69M | 0.14% |
+1,042,135
| New | +$8.69M |
|
88
Omnicell
OMCL
$1.51B
| $8.62M | 0.14% |
197,714
-37,658
| -16% | -$1.64M |
|
89
AbbVie
ABBV
$374B
| $8.47M | 0.14% |
42,886
+682
| +2% | +$135K |
|
90
Johnson & Johnson
JNJ
$429B
| $8.3M | 0.13% |
51,242
+43,445
| +557% | +$7.04M |
|
91
Legend Biotech
LEGN
$6.64B
| $8.24M | 0.13% |
169,134
-200,136
| -54% | -$9.75M |
|
92
Glaukos
GKOS
$5.42B
| $8.21M | 0.13% |
62,983
+7,057
| +13% | +$919K |
|
93
Amgen
AMGN
$153B
| $8.1M | 0.13% |
25,152
-4,376
| -15% | -$1.41M |
|
94
Centene
CNC
$14.8B
| $6.53M | 0.11% |
86,708
-334,750
| -79% | -$25.2M |
|
95
10x Genomics
TXG
$1.66B
| $6.36M | 0.1% |
281,881
-26,430
| -9% | -$597K |
|
96
Illumina
ILMN
$15.2B
| $5.89M | 0.1% |
45,196
+1,600
| +4% | +$209K |
|
97
Altimmune
ALT
$325M
| $5.3M | 0.09% |
863,660
+263,660
| +44% | +$1.62M |
|
98
Merck
MRK
$210B
| $4.8M | 0.08% |
42,233
-32,476
| -43% | -$3.69M |
|
|
WAY
99
Waystar Holding Corp
WAY
$6.53B
| $4.19M | 0.07% |
150,202
+202
| +0.1% | +$5.63K |
|
100
Pfizer
PFE
$141B
| $4.08M | 0.07% |
141,075
+52,461
| +59% | +$1.52M |
|